Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Sponsor: Kumquat Biosciences Inc.
Summary
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Official title: A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
13
Start Date
2024-12-09
Completion Date
2027-03
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
KQB198
Oral KQB198
Dasatinib
Oral dasatinib
Locations (29)
University of California, San Francisco (UCSF)
San Francisco, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Moffitt Cancer Center
Tampa, Florida, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Duke University Medical Center
Durham, North Carolina, United States
Oncology Hematology Cincinnati
Cincinnati, Ohio, United States
Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations
Nashville, Tennessee, United States
Texas Oncology Austin Central
Austin, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
CHRU de Tours - Hopital Bretonneau
Tours, Centre-Val de Loire, France
AP-HM - Hopital de la Timone
Marseille, France
Medizinische Hochschule Hannover (MHH)
Hanover, Lower Saxony, Germany
Universitaetsklinikum Jena
Jena, Thuringia, Germany
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Bologna, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Lazio, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Milan, Lombardy, Italy
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Gelderland, Netherlands
Aidport Sp. z o.o.
Poznan, Greater Poland Voivodeship, Poland
Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii
Gdansk, Pomeranian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
Gdansk, Pomeranian Voivodeship, Poland
Pratia Onkologia Katowice
Katowice, Silesian Voivodeship, Poland
Hospital Regional Universitario de Malaga
Málaga, Andalusia, Spain
Institut Catala d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Catalonia, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hammersmith Hospital
London, Greater London, United Kingdom
Nottingham University Hospitals
Nottingham, Nottinghamshire, United Kingdom